AIM ImmunoTech (NYSE American: AIM) has announced the signing of an agreement with Thermo Fisher Scientific’s (NYSE: TMO) PPD clinical research business to design its Phase 3 clinical trial for Ampligen in the treatment of late-stage pancreatic cancer.
AIM has reported positive progress in progression-free survival, overall survival, and safety in its Phase 2 DURIPANC study of Ampligen and durvalumab, a joint collaboration between AIM, AstraZeneca (NYSE: AZN), and Erasmus Medical Center in the Netherlands.
In a statement, Thomas K. Equels, CEO of AIM, commented, “The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca’s durvalumab in the treatment of late-stage pancreatic cancer is producing promising results. Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer. AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor. Pancreatic cancer is a deadly unmet medical need – and AIM believes that Ampligen could be a gamechanger in the treatment of pancreatic cancer.”
